Conferences
ASCO GU 2024: Longitudinal Tumor-Informed ctDNA Assay and Patient Outcomes in Testicular Cancer
January 27, 2024
ASCO GU 2024: Nivolumab plus Cabozantinib vs Sunitinib for Previously Untreated Advanced RCC: Results from 55-Month Follow-up of the CheckMate 9ER Trial
January 27, 2024
ASCO GU 2024: Evaluating Prognostic Models for Stage I Seminoma Within the Randomised Trial of Imaging and Surveillance in Seminoma Testis (TRISST)
January 27, 2024
ASCO GU 2024: Survivorship Issues Beyond 2 Years After Treatment in Testicular Germ Cell Tumors: Experience from a Large Center in the United Kingdom
January 27, 2024
ASCO GU 2024: Discussant: Adjuvant Treatment for RCC – Strategies on How to Optimize Patient Selection for The New Standard of Care
January 27, 2024
ASCO GU 2024: Overall Survival Results from the Phase 3 KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell RCC
January 27, 2024